Founded in 2021 by Aditum Bio, Versanis is built around a drug licensed from Novartis. The antibody, called bimagrumab, is designed to block cellular communication via two types of protein regulators and is being studied in people who are overweight or obese.
Lilly’s planned purchase of Versanis is the latest in a monthlong M&A streak that’s included acquisitions of Dice Therapeutics, Sigilon Therapeutics and Emergence Therapeutics.
The dealmaking gives Lilly new drug candidates in areas of research it has prioritized, like immune diseases, cancer and obesity. Its recent success developing drugs for the latter condition has fueled a stock price surge that’s made it the most valuable pharmaceutical company in the world.
Lilly’s most advanced drug in testing for weight loss, an injection called Mounjaro, targets a hormone called GLP-1, similar to Novo Nordisk’s wildly popular diabetes and obesity drugs Ozempic and Wegovy. Another promising medicine that’s not as far along also targets GLP-1, as well as two other hormones. READ MORE
by Ned Pagliarulo
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.